Searchable abstracts of presentations at key conferences in endocrinology

ea0049ep35 | Adrenal cortex (to include Cushing's) | ECE2017

Treatment of adrenal insufficiency with hydrocortisone dual-release formulation: glycometabolic profile and health-related quality of life

Mongioi Laura Maria , Condorelli Rosita Angela , Cimino Laura , La Vignera Sandro , Calogero Aldo Eugenio

Introduction: Treatment of adrenal insufficiency (AI) in the last years has been object of important changes due to the development of a dual-release preparation of hydrocortisone (Plenadren®). Hydrocortisone dual-release therapy contemplates a once-daily tablet that allows more closely mimicking the physiological circadian rhythm cortisol, thus avoiding overexposure.Objective: The aim of the study was to value effects of Plenadren administration on...

ea0026p85 | Endocrine tumours and neoplasia | ECE2011

Comments on a series of patients affected by MEN1

Veltri F , Fusco A , Lugli F , D'Uonnolo A , Lorusso M , Cimino V , Pontecorvi A , De Marinis L

Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant disorder characterized by variable combination of more than 20 types of endocrine and non-endocrine tumors: typically parathyroid glands, pancreatic islet cells and anterior pituitary gland are involved. We studied 20 patients (10M and 10F), affered to our Pituitary Unit in a period of 10 years. All patients had clinical diagnostic criteria suspected for MEN1 (presence of two endocrine tumors at least) and und...

ea0014p606 | (1) | ECE2007

Validation of different insulin sensitivity indices in GH deficiency children using roc curve analysis

Baldelli R , Bellone S , Corneli G , Giampietro A , Cimino V , Pontecorvi A , De Marinis L , Bona G

Insulin sensitivity in GHD patients tends to decrease with age and variations in body composition. Several indices of insulin sensitivity have been considered and among these HOMA, ISI and QUICKI are based on mathematical calculations taking into account glucose and/or insulin levels either in basal conditions or after OGTT. Aim of present study was to validate the different indices in a population of pre-pubertal GHD children (n=66) by ROC curve analysis. All patients ...

ea0016p91 | Bone and calcium | ECE2008

Determinants of spinal deformities in adult patients with untreated growth hormone deficiency (GHD)

Mazziotti Gherardo , Bianchi Antonio , Bonadonna Stefania , Cimino Vincenzo , Fusco Alessandra , Patelli Ilaria , De Marinis Laura , Giustina Andrea

Adult GHD patients may have reduced BMD with high risk of vertebral and non-vertebral fractures which is thought to be reverted by long-term rhGH replacement therapy. In this study we aimed at identifying the determinant factors of vertebral fractures, as assessed by a radiological morphometric approach, in a cohort of adult patients with untreated GHD. Forty-two patients (27 males, 15 females; median age: 48 years, range: 30–67) with untreated severe (as defined by a pea...

ea0014oc2.5 | Bone & calcium metabolism | ECE2007

Effect of gonadal status on baseline and after rhGH treatment prevalence of spinal deformities in adult patients with growth hormone deficiency (GHD)

Mazziotti Gherardo , Bianchi Antonio , Bonadonna Stefania , Nuzzo Monica , Cimino Vincenzo , Fusco Alessandra , Marinis Laura De , Giustina Andrea

Adult GHD patients may have reduced BMD, which is thought to be reverted by long-term rhGH replacement therapy. We have recently reported high prevalence of vertebral osteoporotic deformities in untreated adult GHD patients. Gonadal status is the main determinant of bone loss in patients with primary form of osteoporosis.In this cross-sectional study, we investigated whether the prevalence and degree of spinal deformities in adults with treated or untrea...

ea0011p546 | Endocrine tumours and neoplasia | ECE2006

Cell proliferation and outcome of GH-secreting pituitary adenomas

De Marinis L , Bianchi A , Tilaro L , Doglietto F , Veltri F , Vellone GV , Lugli F , Fusco A , Cimino V , Pontecorvi A , Lauriola L

In order to investigate the correlations between immunohistochemical picture with proliferative index (Ki-67), the clinical course and outcome of GH-secreting pituitary adenomas not cured by neurosurgery, we studied 41 consecutive acromegalic patients (M 12, F 29; aged 43±10.8 yr) previously undergone neurosurgical resection of adenoma. Two patients underwent neurosurgical intervention at least twice. Post-surgical follow-up ranged from 6 to 36 months and all patients rec...

ea0070aep665 | Pituitary and Neuroendocrinology | ECE2020

Assessment of disease control in patients with acromegaly treated with long-acting somatostatin analogs (SMSa) varies according to the time when IGF-I levels are measured during the month following the injection

Cristina Albrici , Lecoq Anne-Lise , Vialon Magaly , Solange Grunenwald , Cocco Aldo , Hamdi Safouane , Vincenzo Cimino , Maione Luigi , Caron Philippe , Chanson Philippe

Introduction: Acromegaly is associated with multiple comorbidities and excess mortality. However, disease burden is reduced by maintaining IGF-1 (and/or GH) levels under safe levels. First generation long-acting SMSa, administered at monthly intervals, represent the first line medical treatment. According to guidelines, its efficacy is evaluated through IGF-I measurements. However, there are no data indicating the optimal time for measuring IGF-I levels after the SMSa injectio...

ea0029p847 | Endocrine tumours and neoplasia | ICEECE2012

Clinical and morphological characterization of C cell hyperplastic and neoplastic lesions of thyroid

Lugli F. , Fusco A. , Bianchi A. , Milardi D. , Cimino V. , Piacentini S. , Celico M. , Lanza P. , Raffaelli M. , Lombardi C. , Fadda G. , Bellantone R. , Pontecorvi A. , Rindi G. , De Marinis L.

Introduction: Medullary thyroid carcinoma (MTC) and C cell hyperplasia (CCH) have a variable clinical presentation and prognosis and few data are available on the correlation between immunohistochemical characterization (IIC) and clinical behavior.Aim: We studied the clinical and morphological characterization of CCH and MTC and we evaluated IIC expression of PTTG-1, SSTR2A, VEGFR-1, VEGFR-2 and VEGFR-3 in 23 cases of CCH and/or MTC, correlating it with ...

ea0022p93 | Bone/Calcium | ECE2010

Glucocorticoid replacement therapy and vertebral fractures in hypopituitary adult males with GH deficiency

Mazziotti Gherardo , Porcelli Teresa , Bianchi Antonio , Cimino Vincenzo , Mejia Carola , Patelli Ilaria , Fusco Alessandra , Giampietro Antonella , De Marinis Laura , Giustina Andrea

GH deficiency (GHD) and excess of glucocorticoids are associated with increased risk of fragility fractures. Most adult GHD patients have other pituitary deficiencies, but it is unclear whether these deficiencies or their overreplacement therapies may influence the bone disease occurring in GHD. The aim of this study was to evaluate whether the prevalence of vertebral fractures may be influenced by glucocorticoid replacement therapy in hypopituitary males with GHD. We studied ...

ea0020p550 | Neuroendocrinology, Pituitary and Behaviour | ECE2009

Growth hormone receptor polymorphism and the effects of pegvisomant in acromegaly

Bianchi Antonio , Mazziotti Gherardo , Tilaro Laura , Cimino Vincenzo , Porcelli Teresa , Mormando Marilda , Tartaglione Linda , Pontecorvi Alfredo , Giustina Andrea , De Marinis Laura

Clinical trials have demonstrated that pegvisomant therapy is highly efficacious, normalizing serum IGF-I levels in the majority of patients with acromegaly. Multiple factors could influence the dose of pegvisomant required to normalize IGF-I, that ranging from 10 to 40 mg/day. However, the determinants of this variability are unknown and, to date, there is no specific recommendation to adjust the dose to the type of patient. Lack of exon 3 of the Growth Hormone receptor (d3-G...